Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...
On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...
Merck said its “once-in-a-lifetime” drug Keytruda could be subject to price reductions under the Inflation Reduction Act, which would lead to a … ...
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...
Li Auto LI has revealed the first images of its new all-electric SUV, the Li i8. This marks a big step for the Chinese automaker as it is moving beyond its popular hybrid-like EREVs (Extended ...
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...
Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...
Li Auto’s (NASDAQ: LI) stock climbed nearly 15% on Tuesday after the company revealed the first images of its new electric SUV, the Li i8. The i8 is Li Auto’s first electric SUV, and it’s ...
Automobile company Li Auto (LI) stock soared after the company teased about its first all-electric SUV, the Li i8. The company released images of the new model, boosting investor optimism ahead of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback